07:00 , Jun 28, 2004 |  BioCentury  |  Finance

Ebb & Flow

When FDA grants Fast Track designation or an SPA, investors need to remember that the FDA action is related to an indication where there's unmet need on the one hand, or to a trial design...
07:00 , Jun 23, 2004 |  BC Extra  |  Financial News

Rejuvenon raises $37 million

Rejuvenon (The Woodlands, Texas) raised $37 million in a series B round led by Schroder Ventures Life Sciences. Rejuvenon in-licenses and develops small molecules to treat cancer and metabolic diseases. The company's RC1291 ghrelin mimetic...
07:00 , Jun 28, 2001 |  BC Extra  |  Financial News

VitaGen raises $15 million

VitaGen (San Diego, Calif.), which is in Phase I testing of its Extracorporeal Liver Assist Device (ELAD), raised $15 million in a private financing. Investors included JP Morgan Partners; BD Ventures; Merrill Lynch Ventures; Perseus...
08:00 , Nov 24, 1997 |  BioCentury  |  Finance

Bayer beware

Peter Stadler, head of technical operations biotechnology at Bayer AG , is warning Europe's venture capitalists and institutions to tread carefully when they look to invest in European biotech. Having successfully raised huge sums of...
07:00 , Sep 7, 1993 |  BC Week In Review  |  Clinical News

Peptide enzymes data

Baylor researchers reported in the latest Proceedings of the National Academy of Sciences that they have developed two peptides 29 amino acids long, one of which, ChPepz, mimics the active site of alpha-chymotrypsin. The other,...